急性呼吸窘迫综合征的生物标志物研究进展  

Research progress of biomarkers of acute respiratory distress syndrome

作　　者：郭彦利[1] 邱颖[1] 陈满秋[1] 

机构地区：[1]吉林大学第一医院日间观察病房,长春130000

出　　处：《中华急诊医学杂志》2016年第4期542-545,共4页Chinese Journal of Emergency Medicine

摘　　要：急性呼吸窘迫综合征（ARDS）是一种急性肺部炎症损伤性疾病，以肺泡-毛细血管膜损伤导致通透性升高，引起肺间质和肺泡水肿，肺泡塌陷和气体交换障碍为特征，临床表现为顽固性低氧血症、进行性呼吸窘迫和非心源性肺水肿。ARDS病死率极高，约27％-45％。为了提高ARDS诊断的特异度，2012年美国医学协会杂志出版了修订后的定义，但是修订后的定义没有采用新的生物标志物或参数。随着对ARDS病理生理学认识的进展，炎症反应引起的各种体液因素和来自损伤组织或活化的细胞的分子将可能成为应用于临床实践的潜在生物标志物。本文对ARDS潜在的标志物进行综述。ARDS is a type of acute diffuse lung injury, characterized by inflammation leading to increased pulmonary vascular permeability and loss of aerated lung tissue, the clinical manifestations are refractory hypoxia, progressive respiratory distress and non cardiac pulmonary edema.ARDS mortality rate is very high, especially in patients with severe ARDS, about 27%-45%. In order to improve diagnostic specificity, a revised definition was published in JAMA in 2012, but no new biomarkers or parameters were adopted.Along with the progress in understanding the pathophysiology of ARDS, a variety of humoral factors by inflammation and molecules derived from injured tissues or activated cells may be potential biomarkers for clinical.

关 键 词：急性呼吸窘迫综合征 生物标志物 非心源性肺水肿 ARDS 气体交换障碍 损伤性疾病 病理生理学 肺部炎症 

分 类 号：R563.8[医药卫生—呼吸系统]